To play this presentation please log in.
Don't have an account?
Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.
Faculty
Faculty
Beth Faiman
PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO
Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio
Adult Nurse Practitioner, Department of Hematology and Medical Oncology
Case Comprehensive Cancer Center, Cleveland, Ohio
Member, Population and Cancer Prevention Program
Faculty
Hans Lee
MD
Sarah Cannon Research Institute, Nashville, Tennessee
Director, Multiple Myeloma Research
Nurse
Mary Steinbach
PhD-c, DNP, FNP-C, APRN
Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah
Lead Ambulatory Advanced Practice Clinician, Division of Hematology
Moderator
Natalie S Callander
MD
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Professor of Medicine, Director, Myeloma Clinical and Cellular Therapy Program
TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of multiple myeloma (MM).
PURPOSE STATEMENT
By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with MM.
DESIRED LEARNING OUTCOME
At the conclusion of this activity, the learner will be able to self-report understanding of the logistical and practical requirements associated with novel therapies for relapsed/refractory (R/R) MM in order to educate, counsel and assist patients and their families in decision-making.
At the end of the activity, learners will also be able to
- Consider published research findings and other clinical factors that affect the best-practice selection, sequencing and combining of established agents and regimens in the care of patients with R/R MM.
- Evaluate the biological rationale for chimeric antigen receptor T-cell therapy directed at B-cell maturation antigen (BCMA) as a targeted therapeutic strategy in MM, and discuss with patients when and if this novel strategy should be considered.
- Educate patients with R/R MM about the mechanism of action of, available and emerging data with and current clinical role of BCMA- and non-BCMA-directed bispecific antibodies.
- Review recently presented clinical research findings establishing the definitive efficacy of BCMA-directed antibody-drug conjugate therapy for R/R MM, and recognize the current clinical role of this form of treatment.
- Appreciate the mechanism of action of, unique characteristics of and available and emerging data with the various cereblon E3 ligase modulators under development, to prepare for their potential clinical availability for patients with R/R MM.
- Implement a plan of care to recognize and manage side effects and toxicities associated with commonly used, recently approved and promising emerging systemic therapies for MM.
ACCREDITATION STATEMENT
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
CREDIT DESIGNATION STATEMENT
This educational activity for 1.5 contact hours is provided by RTP during the period of July 17, 2026, to July 17, 2027.
This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.
ONCC/ILNA CERTIFICATION INFORMATION
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/ONS2026/RRMultipleMyeloma/ILNA.
ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.
PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
FOR SUCCESSFUL COMPLETION
To receive credit for this activity, the participant should review the NCPD information, watch the video and fill out the evaluation.
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess relevant financial relationships with faculty, planners and managers of NCPD activities. Relevant financial relationships are identified and mitigated through a relevant financial relationship mitigation process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent nurse reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
Dr Faiman is on advisory committees and has consulting agreements with Janssen Biotech Inc and Sanofi.
Dr Lee has consulting agreements (paid to institution) with AbbVie Inc, Alexion Pharmaceuticals, Allogene Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Legend Biotech, Medline, Pfizer Inc, Predicta Biosciences, Regeneron Pharmaceuticals Inc, Sanofi, and Takeda Pharmaceuticals USA Inc; has consulting agreements (paid to self) with Alexion Pharmaceuticals, Allogene Therapeutics, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Menarini Group, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, and Takeda Pharmaceuticals USA Inc; has contracted research with AbbVie Inc, Alexion Pharmaceuticals, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Menarini Group, Moderna, Regeneron Pharmaceuticals Inc, and Takeda Pharmaceuticals USA Inc; and is on data and safety monitoring boards/committees for Allogene Therapeutics and Takeda Pharmaceuticals USA Inc.
Ms Steinbach is on advisory committees with Bristol Myers Squibb, Johnson & Johnson, Pfizer Inc, and Regeneron Pharmaceuticals Inc; has contracted research with and is on speakers bureaus for Johnson & Johnson, Pfizer Inc, and Regeneron Pharmaceuticals Inc.
All of the relevant financial relationships above have been mitigated.
MODERATOR
Dr Callander has no relevant financial relationships to disclose.
RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners (including Nurse Planner Sharon Cusanza, MSN, RN, NEA-BC, CHCP), scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This activity is supported by educational grants from Bristol Myers Squibb, GSK, and Regeneron Pharmaceuticals Inc.
Release date: July 17, 2026
Expiration date: July 17, 2027
There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.